Individual lymph nodes: “See it and Zap it”

Tree, 2013, Stereotactic body radiotherapy for oligometastases, Lancet Oncol, 1, e28, 10.1016/S1470-2045(12)70510-7 De Bleser, 2017, Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer, Curr Opin Urol, 27, 587, 10.1097/MOU.0000000000000441 Otake, 2019, Stereotactic Radiotherapy for Oligometastasis, Cancers (Basel), 11, E133, 10.3390/cancers11020133 Hellman, 2005, Importance of local control in an era of systemic therapy, Nat Clin Pract Oncol, 2, 60, 10.1038/ncponc0075 Bouman-Wammes, 2017, Benefits of using stereotactic body radiotherapy in patients with metachronous oligometastases of hormone-sensitive prostate cancer detected by [18F]fluoromethylcholine PET/CT, Clin Genitourin Cancer, 15, e773, 10.1016/j.clgc.2017.03.009 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Steuber, 2018, Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study, Eur Urol Focus, 10.1016/j.euf.2018.02.015 Timmerman, 2009, Local surgical, ablative, and radiation treatment of metastases, CA Cancer J Clin, 59, 145, 10.3322/caac.20013 Aitken, 2015, Stereotactic body radiotherapy for liver metastases, Clin Oncol (R Coll Radiol), 27, 307, 10.1016/j.clon.2015.01.032 Shultz, 2014, Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer, J Thorac Oncol, 9, 1426, 10.1097/JTO.0000000000000317 Comito, 2014, Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach, BMC Cancer, 14, 619, 10.1186/1471-2407-14-619 Andratschke, 2018, The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases, BMC Cancer, 18, 283, 10.1186/s12885-018-4191-2 Scorsetti, 2018, Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up, Radiat Oncol, 13, 234, 10.1186/s13014-018-1185-9 Lancia, 2019, Oligometastatic prostate cancer: the game is afoot, Cancer Treat Rev, 73, 84, 10.1016/j.ctrv.2019.01.005 Palacios-Eito, 2019, Oligometastases in prostate cancer: ablative treatment, World J Clin Oncol, 10, 38, 10.5306/wjco.v10.i2.38 Chance, 2017, Stereotactic ablative radiotherapy for adrenal gland metastases: factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity, Pract Radiat Oncol, 7, e195, 10.1016/j.prro.2016.09.005 Ippolito, 2015, SBRT: a viable option for treating adrenal gland metastases, Rep Pract Oncol Radiother, 20, 484, 10.1016/j.rpor.2015.05.009 Moghul, 2019, Detection rates of recurrent prostate cancer: 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review, Ther Adv Urol, 11, 10.1177/1756287218815793 Fowler, 2001, Is alpha/beta for prostate tumors really low?, Int J Radiat Oncol Biol Phys, 50, 1021, 10.1016/S0360-3016(01)01607-8 Ponti, 2017, Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy, Eur Urol Focus, 3, 538, 10.1016/j.euf.2017.07.006 Taylor, 2009, Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer, Cancer, 115, 2388, 10.1002/cncr.24283 Detti, 2015, Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer, World J Urol, 33, 1197, 10.1007/s00345-014-1427-x Muldermans, 2016, Stereotactic body radiation therapy for oligometastatic prostate cancer, Int J Radiat Oncol Biol Phys, 95, 696, 10.1016/j.ijrobp.2016.01.032 Pasqualetti, 2016, [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results, Radiat Oncol, 11, 9, 10.1186/s13014-016-0586-x Laliscia, 2017, Clinical outcomes of stereotactic body radiotherapy in oligometastatic gynecological cancer, Int J Gynecol Cancer, 27, 396, 10.1097/IGC.0000000000000885 Siva, 2018, Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial, Eur Urol, 74, 455, 10.1016/j.eururo.2018.06.004 Winkel, 2018, Simulated dosimetric impact of online replanning for stereotactic body radiation therapy of lymph node oligometastases on the 1.5T MR-linac, Acta Oncol, 3, 1 Noel, 2015, Comparison of onboard low-field magnetic resonance imaging versus onboard computed tomography for anatomy visualization in radiotherapy, Acta Oncol, 54, 1474, 10.3109/0284186X.2015.1062541 Raaymakers, 2017, First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment, Phys Med Biol, 62, L41, 10.1088/1361-6560/aa9517 Werensteijn-Honingh, 2019, Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: multi-fraction treatment of pelvic lymph node oligometastases, Radiother Oncol, 134, 50, 10.1016/j.radonc.2019.01.024 Winkel, 2018, Dose escalation and hypofractionation for SBRT of lymph node oligometastases on the 1.5T MRI-Linac, Radiother Oncol, 127, S443, 10.1016/S0167-8140(18)31158-7 Henke, 2016, Simulated online adaptive magnetic resonance-guided stereotactic body radiation therapy for the treatment of oligometastatic disease of the abdomen and central thorax: characterization of potential advantages, Int J Radiat Oncol Biol Phys, 96, 1078, 10.1016/j.ijrobp.2016.08.036 Heerkens, 2017, Pancreatic tumor motion reduction by use of a custom abdominal corset, Phys Imaging Radiat Oncol, 2, 7, 10.1016/j.phro.2017.02.003 Winkel, 2017, Automated full-online replanning of SBRT lymph node oligometastases for the MR-linac, Radiother Oncol, 123, S904, 10.1016/S0167-8140(17)32195-3 Winkel, 2019, Evaluation of plan adaptation strategies for stereotactic radiotherapy of lymph node oligometastases using online magnetic resonance image guidance, Phys Imaging Radiat Oncol, 9, 58, 10.1016/j.phro.2019.02.003 Winkel, 2019, Dosimetric benefit of the first clinical SBRT of lymph node oligometastases on the 1.5T MR-linac, ESTRO van Herk, 2000, The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy, Int J Radiat Oncol Biol Phys, 47, 1121, 10.1016/S0360-3016(00)00518-6 Gordon, 2007, Convolution method and CTV-to-PTV margins for finite fractions and small systematic errors, Phys Med Biol, 52, 1967, 10.1088/0031-9155/52/7/013 de Boer, 2001, A protocol for the reduction of systematic patient setup errors with minimal portal imaging workload, Int J Radiat Oncol Biol Phys, 50, 1350, 10.1016/S0360-3016(01)01624-8 Tijssen, 2019, MRI commissioning of 1.5T MR-linac systems – a multi-institutional study, Radiother Oncol, 132, 114, 10.1016/j.radonc.2018.12.011 Stroom, 2002, Geometrical uncertainties, radiotherapy planning margins, and the ICRU-62 report, Radiother Oncol, 64, 75, 10.1016/S0167-8140(02)00140-8 Tanderup, 2014, MRI-guided brachytherapy, Semin Radiat Oncol, 24, 181, 10.1016/j.semradonc.2014.02.007 Sturdza, 2016, Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study, Radiother Oncol, 120, 428, 10.1016/j.radonc.2016.03.011 Pötter, 2018, The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies, Clin Transl Radiat Oncol, 9, 48, 10.1016/j.ctro.2018.01.001 Rijkmans, 2014, Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy, Gynecol Oncol, 135, 231, 10.1016/j.ygyno.2014.08.027 Tanderup, 2016, Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer, Radiother Oncol, 120, 441, 10.1016/j.radonc.2016.05.014 Nguyen, 2012, Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy, J Urol, 188, 1151, 10.1016/j.juro.2012.06.010 Fischer-Valuck, 2017, Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system, Adv Radiat Oncol, 2, 485, 10.1016/j.adro.2017.05.006 Witte, 2004, The effects of target size and tissue density on the minimum margin required for random errors, Med Phys, 31, 3068, 10.1118/1.1809991 Wiersema, 2017, First IGRT results for SBRT bone and lymph node oligometastases within the pelvic region, Radiother Oncol, 123, S1006, 10.1016/S0167-8140(17)32273-9 Pantarotto, 2009, Motion analysis of 100 mediastinal lymph nodes: potential pitfalls in treatment planning and adaptive strategies, Int J Radiat Oncol Biol Phys, 74, 1092, 10.1016/j.ijrobp.2008.09.031 Yorke, 2016, Kilovoltage imaging of implanted fiducials to monitor intrafraction motion with abdominal compression during stereotactic body radiation therapy for gastrointestinal tumors, Int J Radiat Oncol Biol Phys, 95, 1042, 10.1016/j.ijrobp.2015.11.018 McPartlin, 2016, MRI-guided prostate adaptive radiotherapy – a systematic review, Radiother Oncol, 119, 371, 10.1016/j.radonc.2016.04.014 Kerkhof, 2009, Intrafraction motion in patients with cervical cancer: the benefit of soft tissue registration using MRI, Radiother Oncol, 93, 115, 10.1016/j.radonc.2009.07.010 Nijkamp, 2012, Repeat CT assessed CTV variation and PTV margins for short- and long-course pre-operative RT of rectal cancer, Radiother Oncol, 102, 399, 10.1016/j.radonc.2011.11.011 Schippers, 2014, Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with cervical cancer, Radiother Oncol, 111, 442, 10.1016/j.radonc.2014.05.013